Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MK-3866
- Development stage
- Phase 1
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
MK-3866 is a small molecule metallo-beta-lactamase (MBL) inhibitor developed by Merck Sharp & Dohme for the treatment of bacterial infections, particularly those caused by resistant gram-negative bacteria expressing MBLs. Its primary mechanism is to inhibit class B beta-lactamases (metallo-beta-lactamases), thereby restoring the antibacterial activity of beta-lactam antibiotics against resistant strains. The drug was investigated in phase 1 clinical trials, including studies on its pharmacokinetics in patients with renal and hepatic impairment. Development has been discontinued and it has not received regulatory approval for any indication[1][2][3][5].
02
Targets
β-lactamase
Beyond the preview
Go deeper on MK-3866.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MK-3866.